Effect of Polymeric Combinations on Mucoadhesive and Swelling Properties of Orabase Gel Formulations

Abstract:

Topical oral dosage form for anti-inflammation in the oral cavity provides convenience and patient compliance. Formulations of orabase gels composed of poloxamer 407, PVP, PVA, SCMC and/or white petrolatum (WP) and hydrocarbon gel (HG) were investigated for in vitro swelling and mucoadhesion for incorporation of melatonin. The highest detachment time of 18 h with an optimized swelling ratio of 1.3 was obtained from a gel with 55% of WP and HG in the presence of poloxamer 407 and PVP 90. In conclusion, an optimum balancing ratio between hydrocarbons and bioadhesive polymer parts is required to obtain mucoadhesive characteristics of the oral gel.

• Periodical: Advanced Materials Research (Volume 853)
• Pages: 3-8
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.853.3
• Online since: December 2013
• Authors: Aroonsri Priprem*, Chatchanok Nukulkit, Nutjaree Pratheepawanit Johns, Teerasak Damrongrungruang, Nanthiya Wongsangta, Em On Benjavongkulchai
• Keywords: Mucoadhesion, Orabase Gel, Swelling Property

References

[1] V. Hearnden, V. Sankar, K. Hull, D.V. Juras, M. Greenberg, A.R. Kerr, P.B. Lockhart, L.L. Patton, S. Porter and M.H. Thornhill. Adv. Drug Deliv. Rev. Vol. 64 (2012), pp.16-28.

DOI: 10.1016/j.addr.2011.02.008

[2] P.J. Sinko: Martin's physical pharmacy and pharmaceutical sciences : physical chemical and biopharmaceutical principle in the pharmaceutical sciences (Lippincott Williams & Wilkins, Philadelphia 2011).

[3] F.A. Mohammed and H. Khedr. Drug Dev. Ind. Pharm. Vol. 29 (2003), pp.321-337.

[4] G. Amasya, S.Y. Karavana, T. Sen, E. Balogu and N. Tarimci. Turk. J. Pharm. Sci. Vol. 9 (2012), pp.1-12.

[5] M. Innocenti, G. Moscatelli and S. Lopez. J. Pain Symptom Manage. Vol. 24 ( 2002), pp.456-457.

[6] M.A. Attia and H.Y. El Badawy. IJDD. Vol. 2 (2010), pp.314-321.

[7] Y. Sudhakar, K. Kuotsu and A.K. Bandyopadhyay. J. Control. Release Vol. 114 (2006), pp.15-40.

[8] G. Dumortier, J.L. Grossiord, F. Agnely and J.C. Chaumeil. Pharm. Res. Vol. 23 (2006), pp.2709-2728.

DOI: 10.1007/s11095-006-9104-4

[9] N. Salamat-Miller, M. Chittchang and T.P. Johnston. Adv. Drug Deliv. Rev. Vol. 57 (2005), pp.1666-1691.

[10] P.D. Marsh and M.V. Martin. Oral microbiology (Elsevier, Edinburgh 2009).

[11] M. Ishida, N. Nambu and T. Nagai. Chem. Pharm. Bull. Vol. 31 (1983), pp.4561-4564.

[12] I. Diaz-del Consuelo, Y. Jacques, G. -P. Pizzolato, R.H. Guy and F. Falson. Arch. Oral Biol. Vol. 50 (2005), pp.981-987.

DOI: 10.1016/j.archoralbio.2005.04.008

[13] E.S. El-Leithy, D.S. Shaker, M.K. Ghorab and R.S. Abdel-Rashid. AAPS Pharm. Sci. Tech. Vol. 11 (2010), pp.1695-1702.

DOI: 10.1208/s12249-010-9544-3

[14] R.Y. Han, J.Y. Fang, K.C. Sung and O.Y. Hu. Int. J. Pharm. Vol. 177 (1999), pp.201-209.

[15] L. Perioli, V. Ambrogi, D. Rubini, S. Giovagnoli, M. Ricci, P. Blasi and C. Rossi. J. Control. Release. Vol. 95 (2004), pp.521-533.

DOI: 10.1016/j.jconrel.2003.12.018

[16] V.F. Patel, F. Liu and M.B. Brown. J. Control. Release. Vol. 153 (2011), pp.106-116.

[17] N.A. Peppas and P.A. Buri, J. Control. Release. Vol. 2 (1985), pp.257-275.

[18] D. Solomonidou, K. Cremer, M. Krumme and J. Kreuter. J. Biomater. Sci. Polym. Ed. Vol. 12 (2001), pp.1191-1205.

[19] G.P. Andrews, T.P. Laverty and D.S. Jones. Eur. J. Pharm. Biopharm. Vol. 71 (2009), pp.505-518.

[20] R. Shaikh, T. Singh, M. Garland, A. Woolfson and R. Donnelly. J. Pharm. Bioallied Sci. Vol. 3 (2011), pp.89-100.

[21] K. Tamine, T. Ono, K. Hori, J. Kondoh, S. Hamanaka and Y. Maeda. J. Dent. Res. Vol. 89 (2010), pp.1097-1101.

DOI: 10.1177/0022034510370801